JP2017514471A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514471A5 JP2017514471A5 JP2016563936A JP2016563936A JP2017514471A5 JP 2017514471 A5 JP2017514471 A5 JP 2017514471A5 JP 2016563936 A JP2016563936 A JP 2016563936A JP 2016563936 A JP2016563936 A JP 2016563936A JP 2017514471 A5 JP2017514471 A5 JP 2017514471A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- cell
- seq
- antigen
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims description 73
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 67
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 14
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 13
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 13
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- -1 GP240 Proteins 0.000 claims description 10
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 7
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 6
- 102000008579 Transposases Human genes 0.000 claims description 6
- 108010020764 Transposases Proteins 0.000 claims description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 5
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims description 3
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 3
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 3
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 3
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 3
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims description 3
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 3
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 3
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 3
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 3
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 3
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 3
- 241000192019 Human endogenous retrovirus K Species 0.000 claims description 3
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 3
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 3
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 3
- 102000003735 Mesothelin Human genes 0.000 claims description 3
- 108090000015 Mesothelin Proteins 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 claims description 3
- 108010008707 Mucin-1 Proteins 0.000 claims description 3
- 102100023123 Mucin-16 Human genes 0.000 claims description 3
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims description 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims description 3
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims description 3
- 102100035721 Syndecan-1 Human genes 0.000 claims description 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 3
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 3
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 3
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 229950010203 nimotuzumab Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 240000007019 Oxalis corniculata Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 69
- 210000001744 T-lymphocyte Anatomy 0.000 description 37
- 230000009261 transgenic effect Effects 0.000 description 16
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 238000012258 culturing Methods 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983298P | 2014-04-23 | 2014-04-23 | |
| US201461983103P | 2014-04-23 | 2014-04-23 | |
| US61/983,103 | 2014-04-23 | ||
| US61/983,298 | 2014-04-23 | ||
| PCT/US2015/027277 WO2015164594A1 (en) | 2014-04-23 | 2015-04-23 | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023077A Division JP2020072755A (ja) | 2014-04-23 | 2020-02-14 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514471A JP2017514471A (ja) | 2017-06-08 |
| JP2017514471A5 true JP2017514471A5 (enExample) | 2018-05-24 |
Family
ID=53055122
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563936A Withdrawn JP2017514471A (ja) | 2014-04-23 | 2015-04-23 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2020023077A Pending JP2020072755A (ja) | 2014-04-23 | 2020-02-14 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2022074648A Pending JP2022093564A (ja) | 2014-04-23 | 2022-04-28 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2023130951A Pending JP2023138812A (ja) | 2014-04-23 | 2023-08-10 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023077A Pending JP2020072755A (ja) | 2014-04-23 | 2020-02-14 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2022074648A Pending JP2022093564A (ja) | 2014-04-23 | 2022-04-28 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2023130951A Pending JP2023138812A (ja) | 2014-04-23 | 2023-08-10 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20170158749A1 (enExample) |
| EP (1) | EP3134437A1 (enExample) |
| JP (4) | JP2017514471A (enExample) |
| KR (1) | KR20160145802A (enExample) |
| CN (1) | CN106459924A (enExample) |
| AU (1) | AU2015249655B2 (enExample) |
| CA (1) | CA2945388A1 (enExample) |
| WO (1) | WO2015164594A1 (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| KR102452767B1 (ko) | 2013-05-14 | 2022-10-12 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| EP3105335B1 (en) | 2014-02-14 | 2019-10-02 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| ES2759260T3 (es) | 2014-04-23 | 2020-05-08 | Juno Therapeutics Inc | Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| FR3026744B1 (fr) | 2014-10-06 | 2024-04-19 | Hopitaux Paris Assist Publique | Methode de generation de progeniteurs de cellules t |
| US10570186B2 (en) | 2014-11-05 | 2020-02-25 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (CAR) to selectively target protein complexes |
| US11253546B2 (en) | 2014-12-15 | 2022-02-22 | The Regents Of The University Of California | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 |
| US10808230B2 (en) | 2015-02-24 | 2020-10-20 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified T cells |
| PL3268470T3 (pl) | 2015-03-11 | 2021-06-14 | Board Of Regents, The University Of Texas System | Polipeptydy transpozazy i ich zastosowania |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| IL257105B (en) | 2015-07-31 | 2022-09-01 | Univ Minnesota | Modified cells and methods of therapy |
| WO2017023859A1 (en) * | 2015-07-31 | 2017-02-09 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting cd56 and uses thereof |
| AU2016323153B2 (en) | 2015-09-15 | 2021-04-22 | Board Of Regents, The University Of Texas System | T-cell receptor (TCR)-binding antibodies and uses thereof |
| EP3368075B1 (en) | 2015-10-27 | 2020-01-29 | Board of Regents, The University of Texas System | Chimeric antigen receptor molecules and uses thereof |
| RU2753695C2 (ru) * | 2015-11-04 | 2021-08-19 | Сол Дж. ПРАЙСМЕН | Химерные рецепторы антигена, нацеленные на her2 |
| CA3004738A1 (en) * | 2015-11-09 | 2017-05-18 | Aperisys, Inc. | Modified immune cells and uses thereof |
| WO2017132535A1 (en) * | 2016-01-28 | 2017-08-03 | The Regents Of The University Of California | Methods for selectively expanding and enriching cells transduced with chimeric antigen receptors and treating hiv infection |
| ES2879700T3 (es) * | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| WO2017177149A2 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| WO2017184968A1 (en) * | 2016-04-22 | 2017-10-26 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| IL311985A (en) * | 2016-06-06 | 2024-06-01 | Univ Texas | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof |
| US20200208111A1 (en) * | 2016-06-09 | 2020-07-02 | Branden S. Moriarity | Genome-edited nk cell and methods of making and using |
| CN107523547A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抑制性抗体的car‑t细胞及其用途 |
| US11583555B2 (en) | 2016-06-24 | 2023-02-21 | University of Pittsburgh—of the Commonwealth System of Higher Education | Genetic re-engineering of immune cells to improve metabolic fitness for immunotherapy |
| CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| CA3034691A1 (en) | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| CN110121505B (zh) | 2016-12-28 | 2023-08-01 | 株式会社绿十字细胞治疗 | 嵌合抗原受体和表达其的自然杀伤细胞 |
| CA3053294A1 (en) | 2017-02-13 | 2018-08-16 | Assistance Publique - Hopitaux De Paris | Method for generating t cells progenitors |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| AU2018367896B2 (en) | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN107099603A (zh) * | 2017-05-31 | 2017-08-29 | 成都克里斯博生物科技有限公司 | 肿瘤免疫t细胞检测试剂盒和检测方法 |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| JP7210534B2 (ja) * | 2017-07-12 | 2023-01-23 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ | Ｈ３ｋ２７ｍ変異を有するがんの処置のための組成物および方法 |
| CN118206655A (zh) * | 2017-07-25 | 2024-06-18 | 得克萨斯大学体系董事会 | 增强的嵌合抗原受体及其用途 |
| TWI676483B (zh) * | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
| CN107287165A (zh) * | 2017-08-23 | 2017-10-24 | 湖南开启时代生物科技有限责任公司 | 一种car‑t细胞的制备方法 |
| WO2019047932A1 (zh) * | 2017-09-08 | 2019-03-14 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| MX421596B (es) * | 2017-09-29 | 2025-03-14 | Us Health | Receptores de celulas t que reconocen p53 mutado |
| CN107488738B (zh) * | 2017-10-12 | 2020-04-28 | 中国医学科学院肿瘤医院 | 一种预测乳腺癌对曲妥珠单抗联合化疗治疗敏感性的生物标志物 |
| EP3712178A4 (en) | 2017-11-14 | 2021-08-11 | Green Cross Lab Cell Corporation | ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CA3082334A1 (en) * | 2017-11-20 | 2019-05-23 | Julius-Maximilians-Universitat Wurzburg | Cd19cart cells eliminate myeloma cells that express very low levels of cd19 |
| CU24558B1 (es) * | 2017-11-28 | 2021-12-08 | Ct Inmunologia Molecular | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
| CN108070033A (zh) * | 2017-12-12 | 2018-05-25 | 武汉波睿达生物科技有限公司 | 一种3bnc-car分子的构建及其在杀灭hiv-1感染细胞中的应用 |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| MX2020006015A (es) | 2017-12-15 | 2020-10-12 | Univ Leland Stanford Junior | Composiciones y procedimientos para inhibir el agotamiento de celulas t. |
| CN111683971A (zh) | 2017-12-23 | 2020-09-18 | 宇越生医科技股份有限公司 | 医药重组受体组成物及方法 |
| CN111867619A (zh) | 2018-01-03 | 2020-10-30 | 曲生物制品公司 | 过继性细胞治疗的先天寻靶 |
| US11965191B2 (en) | 2018-01-18 | 2024-04-23 | California Institute Of Technology | Programmable protein circuits in living cells |
| TW201940182A (zh) * | 2018-01-22 | 2019-10-16 | 美商安德賽特公司 | Car t 細胞之使用方法 |
| WO2019147604A2 (en) * | 2018-01-23 | 2019-08-01 | Vanderbilt University | Self-antigen specific t-cells as vacines for augmenting engraftment and stability of autologous transfer |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| WO2019173798A1 (en) * | 2018-03-08 | 2019-09-12 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
| US20190247437A1 (en) * | 2018-04-19 | 2019-08-15 | APDN (B.V.I.), Inc. | Engineered lymphocyte compositions, methods and systems |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| CN112672753B (zh) | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| JP7623935B2 (ja) * | 2018-08-07 | 2025-01-29 | パーデュー・リサーチ・ファウンデーション | Ｃａｒ ｔ細胞の若返り |
| CN110862967A (zh) * | 2018-08-27 | 2020-03-06 | 天津天锐生物科技有限公司 | 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk |
| EP3844180A4 (en) | 2018-08-31 | 2022-07-20 | California Institute of Technology | Synthetic protein circuits detecting signal transducer activity |
| JP2021536265A (ja) * | 2018-09-07 | 2021-12-27 | ソティオ，リミティド ライアビリティ カンパニー | 細胞内乳酸濃度を調節するトランス代謝分子と組み合わせたキメラ受容体ポリペプチド及びその治療的使用 |
| CN113164576A (zh) * | 2018-10-05 | 2021-07-23 | 圣安娜儿童癌症研究中心 | 嵌合抗原受体(car)组 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3908653A4 (en) | 2019-01-10 | 2022-11-02 | California Institute of Technology | A synthetic system for tunable thresholding of protein signals |
| EP3914270A4 (en) * | 2019-01-25 | 2023-01-11 | The Trustees of the University of Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING MUTANT RAS |
| CA3130671A1 (en) * | 2019-02-07 | 2020-08-13 | Board Of Regents, The University Of Texas Systems | Glucuronoxylomannan (gxm) receptor chimeric antigen receptors and use thereof |
| AU2020218615B2 (en) * | 2019-02-08 | 2025-01-30 | Biontech Cell & Gene Therapies Gmbh | Treatment involving CAR-engineered T cells and cytokines |
| MX2021009742A (es) | 2019-02-15 | 2021-12-10 | Editas Medicine Inc | Celulas asesinas naturales (nk) modificadas para inmunoterapia. |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| EP3962535A1 (en) | 2019-04-30 | 2022-03-09 | CRISPR Therapeutics AG | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| WO2020247837A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| EP3980530A1 (en) * | 2019-06-07 | 2022-04-13 | Juno Therapeutics, Inc. | Automated t cell culture |
| US20220332780A1 (en) | 2019-09-10 | 2022-10-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| JP2023500671A (ja) * | 2019-11-06 | 2023-01-10 | ベイラー カレッジ オブ メディスン | がんのｔ細胞治療のための細胞傷害性エフェクターメモリーｔ細胞の産生方法 |
| CN115003386A (zh) * | 2019-11-27 | 2022-09-02 | 宾夕法尼亚大学董事会 | 产生抗cd3 scfv和细胞因子的人工抗原呈递细胞 |
| IL293716A (en) * | 2019-12-11 | 2022-08-01 | A2 Biotherapeutics Inc | Lilrb1-based chimeric antigen receptor |
| TW202146431A (zh) * | 2020-02-25 | 2021-12-16 | 英商圭爾醫療有限公司 | 用於經工程化細胞之嵌合受體 |
| CN111253493B (zh) * | 2020-03-05 | 2021-03-23 | 武汉科技大学 | 一种靶向hiv病毒囊膜双位点的嵌合抗原受体及其表达载体和应用 |
| US12264190B2 (en) * | 2020-04-24 | 2025-04-01 | Astrazeneca Ab | Compositions and methods of treating cancer with chimeric antigen receptors |
| AU2021305234A1 (en) | 2020-07-10 | 2023-02-09 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| KR102605723B1 (ko) * | 2020-11-11 | 2023-11-24 | 한국과학기술원 | 키메라 항원 수용체를 위한 타깃 항원 발굴 방법 및 분석 장치 |
| CN114716548B (zh) * | 2021-01-05 | 2024-11-05 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
| US20240327889A1 (en) * | 2021-04-05 | 2024-10-03 | Victor TETS | Regulation of cells and organisms |
| CA3216024A1 (en) * | 2021-04-08 | 2022-10-13 | Artiva Biotherapeutics, Inc. | Chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the same |
| AU2022299551A1 (en) | 2021-06-23 | 2024-01-18 | Editas Medicine, Inc. | Engineered cells for therapy |
| WO2023012584A2 (en) | 2021-08-03 | 2023-02-09 | Genicity Limited | Engineered tcr complex and methods of using same |
| EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
| EP4388017A1 (en) * | 2021-08-20 | 2024-06-26 | Christopher E. Rudd | Compositions and methods for anti-virus chimeric antigen receptor |
| IL316101A (en) | 2022-04-08 | 2024-12-01 | Fate Therapeutics Inc | Skeletal cells refer to solid tumors and their use |
| KR20250004622A (ko) * | 2022-04-08 | 2025-01-08 | 페이트 세러퓨틱스, 인코포레이티드 | 종양 표적화를 위한 키메라 항원 수용체 |
| CN115873803B (zh) * | 2022-11-28 | 2025-06-17 | 上海恩凯细胞技术有限公司 | 提高nk细胞存活和抗肿瘤活性的方法及应用 |
| WO2025106453A1 (en) * | 2023-11-13 | 2025-05-22 | California Institute Of Technology | Synpoptosis circuits for programmable cell death control |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| DE69628154T2 (de) | 1995-03-08 | 2004-03-18 | The Scripps Research Institute, La Jolla | Antigen präsentierendes system und aktivierung von t-zellen |
| WO1997046256A1 (en) | 1996-05-23 | 1997-12-11 | The Scripps Research Institute | Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells |
| EP0973928B1 (en) * | 1997-03-11 | 2010-05-05 | Regents Of The University Of Minnesota | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| MX2008011302A (es) | 2006-03-01 | 2008-11-04 | Janssen Pharmaceutica Nv | Tratamiento de cancer que combina agente de linfodeplecion con linfocitos t citotoxicos y citocinas. |
| WO2008045286A2 (en) | 2006-10-04 | 2008-04-17 | Janssen Pharmaceutica N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US8822647B2 (en) * | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| CN103442768A (zh) * | 2011-01-18 | 2013-12-11 | 宾夕法尼亚大学董事会 | 治疗癌的组合物和方法 |
| PT2668209T (pt) | 2011-01-24 | 2021-04-07 | Gilead Sciences Inc | Anticorpos seletivos para células que apresentam egfr em alta densidade |
| MX347656B (es) * | 2011-04-08 | 2017-05-08 | Baylor College Medicine | Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos. |
| AU2013221672B2 (en) * | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| CA2929087A1 (en) * | 2013-10-31 | 2015-05-07 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
-
2015
- 2015-04-23 CN CN201580026693.4A patent/CN106459924A/zh active Pending
- 2015-04-23 WO PCT/US2015/027277 patent/WO2015164594A1/en not_active Ceased
- 2015-04-23 AU AU2015249655A patent/AU2015249655B2/en not_active Ceased
- 2015-04-23 JP JP2016563936A patent/JP2017514471A/ja not_active Withdrawn
- 2015-04-23 EP EP15721090.7A patent/EP3134437A1/en active Pending
- 2015-04-23 US US15/305,996 patent/US20170158749A1/en not_active Abandoned
- 2015-04-23 CA CA2945388A patent/CA2945388A1/en active Pending
- 2015-04-23 KR KR1020167032607A patent/KR20160145802A/ko not_active Ceased
-
2019
- 2019-10-14 US US16/600,806 patent/US20200102366A1/en not_active Abandoned
-
2020
- 2020-02-14 JP JP2020023077A patent/JP2020072755A/ja active Pending
-
2022
- 2022-04-28 JP JP2022074648A patent/JP2022093564A/ja active Pending
-
2023
- 2023-01-11 US US18/153,025 patent/US20230312675A1/en active Pending
- 2023-08-10 JP JP2023130951A patent/JP2023138812A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514471A5 (enExample) | ||
| Patel et al. | From concept to cure: The evolution of CAR-T cell therapy | |
| Yin et al. | Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors | |
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| Palladini et al. | Virus-like particle display of HER2 induces potent anti-cancer responses | |
| JP7584414B2 (ja) | 複数の免疫細胞タイプの同時増殖のための方法、関連する組成物および癌免疫療法におけるそれらの使用 | |
| ES2989596T3 (es) | Receptores que proporcionan coestimulación dirigida para terapia celular adoptiva | |
| AU2016306209B2 (en) | Bispecific CAR T-cells for solid tumor targeting | |
| AU2014225788B2 (en) | Engager cells for immunotherapy | |
| Kang et al. | Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects | |
| US20210338729A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF | |
| JP2016525881A5 (enExample) | ||
| CN110573177A (zh) | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) | |
| CN107988165A (zh) | 具有改进特异性的修饰的t淋巴细胞 | |
| CN111163758A (zh) | 具有记忆功能的t细胞或b细胞的增强剂、恶性肿瘤复发抑制剂、以及对t细胞或b细胞诱导记忆功能的诱导剂 | |
| JP2025508050A (ja) | Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞 | |
| Fenton et al. | Cellular cancer immunotherapy development and manufacturing in the clinic | |
| Wang et al. | Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma | |
| US11034773B2 (en) | Methods and materials for treating cancer | |
| CN114599400A (zh) | 用于治疗癌症的医药、组合医药、医药组合物、免疫应答细胞、核酸递送介质和制品 | |
| Olivera et al. | Regional and intratumoral adoptive T-cell therapy | |
| TWI817350B (zh) | 與Globo系列抗原結合之嵌合抗原受體及其用途 | |
| JP2022516710A (ja) | Ｃａｒ ｔ細胞の方法及び構築物 | |
| JP2020535832A (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 | |
| Grzywa et al. | Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells |